Exacerbations in COPD: What’s the risk?
How does an exacerbation affect patient quality of life and lung function?
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
In a network meta-analysis (NMA) of 23 randomised controlled trials (RCTs) involving adult COPD patients eligible for triple therapy, 17 of which reported moderate/severe exacerbation endpoint. Analysis based on a Frequentist Fixed Effect (FE) model.
Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.2
Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)6
Relvar Ellipta 92/22mcg is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilation therapy3
Seretide (50 micrograms salmeterol and 500 micrograms fluticasone propionate) is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.